Home
University of Bergen
kenneth dickstein's picture

kenneth dickstein

Emeritus
Department of Clinical Science
  • E-mailkenneth.dickstein@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2024). Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). European Journal of Heart Failure.
  • Show author(s) (2024). Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF. International Journal of Cardiology.
  • Show author(s) (2022). Upgrades from Previous Cardiac Implantable Electronic Devices Compared to De Novo Cardiac Resynchronization Therapy Implantations: Results from CRT Survey-II in the Turkish Population. Turk Kardiyoloji Dernegi Arsivi. 182-191.
  • Show author(s) (2022). The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. Journal of Women's Health. 310-320.
  • Show author(s) (2022). Risk estimates of imminent cardiovascular death and heart failure hospitalization are improved using serial natriuretic peptide measurements in patients With coronary artery disease and type 2 diabetes. Journal of the American Heart Association (JAHA).
  • Show author(s) (2022). Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry. European Journal of Heart Failure. 645-652.
  • Show author(s) (2022). Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure). European Journal of Heart Failure. 1020-1029.
  • Show author(s) (2022). Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. Diabetes Care. 2152-2155.
  • Show author(s) (2022). Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal. 4469-4479.
  • Show author(s) (2022). Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. European Journal of Heart Failure. 308-320.
  • Show author(s) (2022). Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research (CVR). 2478-2487.
  • Show author(s) (2022). Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure. JACC. Heart failure. 623-632.
  • Show author(s) (2022). Multimarker profiling identifies protective and harmful immune processes in heart failure: Findings from BIOSTAT-CHF. Cardiovascular Research (CVR). 1964-1977.
  • Show author(s) (2022). Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence. ESC Heart Failure. 4167-4176.
  • Show author(s) (2022). Heart failure with normal LVEF in BIOSTAT-CHF. International Journal of Cardiology. 85-90.
  • Show author(s) (2022). Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. European Heart Journal. 2224-2234.
  • Show author(s) (2022). Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial. European Journal of Heart Failure. 1239-1248.
  • Show author(s) (2022). Distinct pathophysiological pathways in women and men with heart failure. European Journal of Heart Failure. 13 pages.
  • Show author(s) (2022). Clinical implications of low estimated protein intake in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle.
  • Show author(s) (2022). Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. European Journal of Heart Failure. 9 pages.
  • Show author(s) (2022). Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology.
  • Show author(s) (2022). Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC. Heart failure. 415-427.
  • Show author(s) (2022). Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. ESC Heart Failure. 1-12.
  • Show author(s) (2022). Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF. European Journal of Heart Failure. 43-51.
  • Show author(s) (2022). Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. American Society of Nephrology. Clinical Journal. 228-239.
  • Show author(s) (2021). Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: Insights from the high-risk myocardial infarction database. European Heart Journal: Acute Cardiovascular Care. 127-131.
  • Show author(s) (2020). Cardiac resynchronization therapy in Romania – results from the european society of cardiology CRT survey II. Revista română de cardiologie. 48-55.
  • Show author(s) (2019). Proenkephalin, an opioid system surrogate, as a novel comprehensive renal marker in heart failure. Circulation: Heart Failure. 1-13.
  • Show author(s) (2019). Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. European Journal of Heart Failure. 1-11.
  • Show author(s) (2019). Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. Clinical Research in Cardiology. 1215-1225.
  • Show author(s) (2019). Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. American Heart Journal. 83-90.
  • Show author(s) (2019). Editor’s Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. European Heart Journal: Acute Cardiovascular Care. 231-241.
  • Show author(s) (2019). Differential impact of heart failure with reduced ejection fraction on men and women. Journal of the American College of Cardiology. 29-40.
  • Show author(s) (2019). Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients with Heart Failure: Results from the DEFINE-HF and BIOSTAT-CHF Studies. JAMA cardiology.
  • Show author(s) (2019). Contemporary practice of CRT implantation in scandinavia compared to Europe. Scandinavian Cardiovascular Journal. 9-13.
  • Show author(s) (2019). Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. European Journal of Heart Failure. 218-226.
  • Show author(s) (2019). Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?-findings from the ESC CRT Survey II. Europace. 918-927.
  • Show author(s) (2019). Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. European Journal of Heart Failure.
  • Show author(s) (2018). Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. International Journal of Cardiology. 260-266.
  • Show author(s) (2018). Novel endotypes in heart failure: effects on guideline-directed medical therapy. European Heart Journal. 4269-4276.
  • Show author(s) (2018). Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. Journal of the American College of Cardiology. 1081-1090.
  • Show author(s) (2018). CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? European Journal of Heart Failure. 1039-1051.
  • Show author(s) (2018). Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure. 323-331.
  • Show author(s) (2017). Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. Journal of the American College of Cardiology. 2490-2500.
  • Show author(s) (2017). Serum chloride and sodium interplay in patients with acute myocardial infarction and heart failure with reduced ejection fraction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Circulation: Heart Failure.
  • Show author(s) (2017). Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. Journal of the American Heart Association (JAHA). 1-29.
  • Show author(s) (2017). Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. European Journal of Heart Failure. 673-681.
  • Show author(s) (2017). Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: A subanalysis of the randomized EchoCRT trial. European Heart Journal. 720-726.
  • Show author(s) (2017). Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. European Journal of Heart Failure. 1284-1293.
  • Show author(s) (2017). Intracoronary autologous bone marrow cell transfer after myocardial infarction: The BOOST-2 randomised placebo-controlled clinical trial. European Heart Journal. 2936-2943.
  • Show author(s) (2017). Highly increased Troponin i levels following high-intensity endurance cycling may detect subclinical coronary artery disease in presumably healthy leisure sport cyclists: The North Sea Race Endurance Exercise Study (NEEDED) 2013. European Journal of Preventive Cardiology (EJPC). 885-894.
  • Show author(s) (2017). Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. International Journal of Cardiology. 274-281.
  • Show author(s) (2017). Effect of ularitide on cardiovascular mortality in acute heart failure. New England Journal of Medicine. 1956-1964.
  • Show author(s) (2017). Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT. European Journal of Heart Failure. 80-87.
  • Show author(s) (2017). Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. European Journal of Heart Failure. 627-634.
  • Show author(s) (2017). Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: A prospective European study. European Heart Journal. 1883-1890.
  • Show author(s) (2017). Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Clinical Research in Cardiology. 722-733.
  • Show author(s) (2017). Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure. 271-279.
  • Show author(s) (2017). A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. European Journal of Heart Failure. 635-642.
  • Show author(s) (2017). 'heartfailurematters.org', an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions. European Journal of Heart Failure. 1447-1454.
  • Show author(s) (2016). What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. European Journal of Heart Failure. 66-70.
  • Show author(s) (2016). What constitutes optimal neurohumoral antagonism in chronic heart failure? Heart. 1922-1932.
  • Show author(s) (2016). Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine.
  • Show author(s) (2016). Relation of longitudinal changes in quality of life assessments to changes in functional capacity in patients with heart failure with and without anemia. American Journal of Cardiology. 1482-1487.
  • Show author(s) (2016). Natriuretic peptide levels taken following unplanned admission to a cardiology department predict the duration of hospitalization. European Journal of Heart Failure. 1499-1505.
  • Show author(s) (2016). Geographic differences in patients in a global acute heart failure clinical trial (from the ASCEND-HF Trial). American Journal of Cardiology. 1771-1778.
  • Show author(s) (2016). Effect of gender on outcomes after cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Circulation: Arrhythmia and Electrophysiology.
  • Show author(s) (2016). Circulating galectin-3 levels are increased in patients with ischemic heart disease, but are not influenced by acute myocardial infarction. Cardiology. 398-405.
  • Show author(s) (2016). Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: A subgroup analysis of the EchoCRT trial. European Heart Journal. 49-59.
  • Show author(s) (2016). Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine. 1521-1532.
  • Show author(s) (2016). Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Journal of the American College of Cardiology. 1444-1455.
  • Show author(s) (2016). A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. European Journal of Heart Failure. 716-726.
  • Show author(s) (2015). The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. European Journal of Heart Failure. 329-339.
  • Show author(s) (2015). The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: A subgroup analysis of the EchoCRT trial. European Heart Journal. 1983-1989.
  • Show author(s) (2015). The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): Revised statistical analysis plan and baseline characteristics. European Journal of Heart Failure. 1075-1083.
  • Show author(s) (2015). Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure. 1144-1151.
  • Show author(s) (2015). Recommendations on pre-hospital & early hospital management of acute heart failure: A consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure. 544-548.
  • Show author(s) (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal. 631-638.e7.
  • Show author(s) (2015). Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. American Heart Journal. 290-297.e1.
  • Show author(s) (2015). Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine. 2247-2257.
  • Show author(s) (2015). International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): Rationale for and design of a global registry. European Journal of Heart Failure. 527-533.
  • Show author(s) (2015). Increasing exercise capacity and quality of life of patients with heart failure through Wii gaming: The rationale, design and methodology of the HF-Wii study; A multicentre randomized controlled trial. European Journal of Heart Failure. 743-748.
  • Show author(s) (2015). Effectiveness of an interactive platform, and the ESC/HFA heartfailurematters.org website in patients with heart failure: Design of the multicentre randomized e-Vita heart failure trial. European Journal of Heart Failure. 1310-1316.
  • Show author(s) (2014). The relationship between markers of extracellular cardiac matrix turnover: Infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. European Heart Journal. 395-402.
  • Show author(s) (2014). The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. European Journal of Heart Failure. 289-299.
  • Show author(s) (2014). The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction. European Heart Journal: Acute Cardiovascular Care. 46-55.
  • Show author(s) (2014). Safety and health status following early discharge in patients with acute myocardial infarction treated with primary PCI: a randomized trial. European Journal of Preventive Cardiology (EJPC).
  • Show author(s) (2014). Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. International Journal of Cardiology. 360-367.
  • Show author(s) (2014). Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). Circulation. 958-965.
  • Show author(s) (2014). Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality findings from ASCEND-HF. Circulation: Heart Failure. 918-925.
  • Show author(s) (2014). European Cardiac Resynchronization Therapy Survey II: rationale and design. Europace. 137-141.
  • Show author(s) (2013). Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. International Journal of Cardiology. 1094-1101.
  • Show author(s) (2013). Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. European Journal of Heart Failure. 1419-1428.
  • Show author(s) (2013). Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European Journal of Heart Failure. 1267-1276.
  • Show author(s) (2013). Global variation in quality of care among patients hospitalized with acute heart failure in an international trial findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). Circulation. Cardiovascular Quality and Outcomes. 534-542.
  • Show author(s) (2011). The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. International Journal of Cardiology. 277-282.
  • Show author(s) (2010). The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: A retrospective cohort study. International Journal of Cardiology. 228-233.
  • Show author(s) (2009). The Chemokine Network in Relation to Infarct Size and Left Ventricular Remodeling Following Acute Myocardial Infarction. American Journal of Cardiology. 1179-1183.
  • Show author(s) (2009). Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients With Chronic Heart Failure A Comparative Analysis on Clinical and Prognostic Insights. Circulation: Heart Failure. 549-555.
  • Show author(s) (2009). Rationale and design of Ferinject((R)) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure. 1084-1091.
  • Show author(s) (2009). Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal. 1331-1339.
  • Show author(s) (2009). Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. European Journal of Heart Failure. 1143-1151.
  • Show author(s) (2009). Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine. 2436-2448.
  • Show author(s) (2009). Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet. 1840-1848.
  • Show author(s) (2009). C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. 1187-1194.
  • Show author(s) (2009). C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. European Heart Journal. 1180-1186.
  • Show author(s) (2009). B-type natriuretic peptide is related to histological skeletal muscle abnormalities in patients with chronic heart failure. International Journal of Cardiology. 358-362.
  • Show author(s) (2008). Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. European Journal of Heart Failure. 140-148.
  • Show author(s) (2008). Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure. International Journal of Cardiology. 117-120.
  • Show author(s) (2008). Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. European Journal of Heart Failure. 899-906.
  • Show author(s) (2008). A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure. European Journal of Heart Failure. 89-95.
  • Show author(s) (2007). Usefulness of either or both left and right bundle branch block at baseline or during follow-up for predicting death in patients following acute myocardial infarction. American Journal of Cardiology. 647-650.
  • Show author(s) (2007). Unrecognized glycometabolic disturbance as measured by hemoglobin A(1c) is associated with a poor outcome after acute myocardial infarction. American Heart Journal. 470-476.
  • Show author(s) (2006). The impact of morbid events on survival following hospitalization for complicated myocardial infarction. European Journal of Heart Failure. 74-80.
  • Show author(s) (2006). The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure. European Journal of Heart Failure. 628-633.
  • Show author(s) (2006). Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. American Heart Journal. 927e1-927e6.
  • Show author(s) (2005). Soluble CD40 ligand in acute and chronic heart failure. European Heart Journal. 1101-1117.
  • Show author(s) (2005). Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. American Journal of Medicine. 752-758.
  • Show author(s) (2005). Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAL experience. European Heart Journal. 350-356.
  • Show author(s) (2005). Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy. Journal of Cardiac Failure. 492-497.
  • Show author(s) (2005). Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction? Nature Clinical Practice Cardiovascular Medicine. 440-441.
  • Show author(s) (2005). Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European Heart Journal. 650-61.
  • Show author(s) (2005). Exercise training in congestive heart failure. A review of the current status. Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy. 275-286.
  • Show author(s) (2005). Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). American Heart Journal. 123-131.
  • Show author(s) (2004). The data monitoring experience in the MOXCON trial. European Heart Journal. 174-178.
  • Show author(s) (2004). Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. Journal of the American College of Cardiology. 1970-1976.
  • Show author(s) (2004). Effect of exercise training in patients with heart failure: a pilot study on autonomous balance assessed by heart rate variability. Journal of Cardiovascular Risk. 162-167.
  • Show author(s) (2004). Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers. American Journal of Cardiology. 632-636.
  • Show author(s) (2003). Prognostic usefulness of an increase of N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. American Journal of Cardiology. 91-94.
  • Show author(s) (2000). The use of angiotensin II receptor antagonists in heart failure. Tidsskrift for Den norske legeforening. 817-821.
  • Show author(s) (2000). The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. International Journal of Cardiology. 167-176.
  • Show author(s) (2000). Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. The Lancet. 1582-1587.
  • Show author(s) (2000). Plasma chromogranin A is an independent predictor of survival after acute myocardial infarction. European Heart Journal. 584.
  • Show author(s) (2000). Plasma brain natriuretic peptide as a prognostic indicator in patients with preserved left ventricular systolic function after acute myocardial infarction. Circulation. 609.
  • Show author(s) (2000). Pharmacotherapy following myocardial infarction - a review of current treatment practices. Exp Opin Pharmacother. 1105-1116.
  • Show author(s) (2000). Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. Receptors in Cardiovascular Disease. 4-9.
  • Show author(s) (2000). Improvements in quality of life of symptomatic heart failure patients treated long-term with losartan and captopril: the ELITE II quality of life substudy. European Heart Journal. 464.
  • Show author(s) (2000). Exercise training in heart failure. Time to go beyond surrogate endpoints. European Journal of Heart Failure. 5-6.
  • Show author(s) (2000). Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Journal of the American College of Cardiology. 398-404.
  • Show author(s) (2000). Effects of exercise training on maximal and submaximal endurance capacity in men with congestive heart failure. European Journal of Heart Failure. In press.
  • Show author(s) (2000). Effect of simvastatin in preventing progression of carotid artery stenosis. American Journal of Cardiology. 17-20.
  • Show author(s) (2000). Effect of aerobic exercise training on cytokine levels in patients with congestive heart failure. European Heart Journal. 234.
  • Show author(s) (2000). Are emergency medical admissions dependent on the weather? Tidsskrift for Den norske legeforening. 355-357.
  • Show author(s) (2000). Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. European Journal of Heart Failure. 235-236.
  • Show author(s) (1993). The effect of early converting enzyme inhibition on neurohumoral activycation in acute myocardial infarction. International Journal of Cardiology. 37-45.
Academic lecture
  • Show author(s) (2008). C-reactive protein, infarct size, microvascular obstruction and left ventricular remodeling following acute myocardial infarction.
  • Show author(s) (2005). Living with an implantable cardioverter defibrillator: A qualitative study from one Norwegian centre.
  • Show author(s) (2002). The role of angiotensin II antagonists in heart failure and following myocardial infarction.
  • Show author(s) (2002). State of the art management of myocardial infarction.
  • Show author(s) (2002). Results of recent trials in patients with heart failure following myocardial infarction.
  • Show author(s) (2002). Outpatient heart failure management programs – 4 models New markers of heart failure Determinants of long-term prognosis in heart failure Emerging therapies for heart failure.
  • Show author(s) (2002). Modern Aspects of Heart Failure Management. Recent Acheivements and Future Directions.
  • Show author(s) (2002). Controlling the course of disease in the post-myocardial infarction patient: the OPTIMAAL trial.
  • Show author(s) (2002). Comparison of the Effects of Losartan and Captopril on Mortality and Morbidity in patients following Acute Myocardial Infarction: The OPTIMAAL Trial.
  • Show author(s) (2002). Clinical implications of losartan in the OPTIMAAL study.
  • Show author(s) (2002). Beta-blockers should be withdrawn in decompensated heart failure patients.
  • Show author(s) (2002). Angiotensin II antagonists; are they established therapy in heart failure?
  • Show author(s) (2002). ARBs are as good as ACE inhibitors.
  • Show author(s) (2001). Effect of exercise training on muscle fibre characteristics in patients with heart failure.
  • Show author(s) (1996). N-terminal probrain natriuretic peptide - a new marker of cardiac function and prognosis.
Abstract
  • Show author(s) (2013). The association between heart rate, pulse pressure and clinical outcomes in 16503 patients with myocardial infarction complicated by signs of heart failure or left ventricular dysfunction. European Heart Journal. 349-349.
  • Show author(s) (2013). Early discharge (< 3 days) following primary PCI is safe in low risk patients. European Heart Journal. 246-246.
  • Show author(s) (2013). ESC Heart Failure Guidelines 2012-a review. Journal of Cardiac Failure. S106-S107.
  • Show author(s) (2010). Smokers spend shorter time in hospital than non-smokers following complicated AMI. European Heart Journal. 683-683.
  • Show author(s) (2010). Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. Journal of Cardiac Failure. S73-S74.
  • Show author(s) (2010). Peripheral artery disease as a predictor of outcome in high-risk MI patients: pooled analysis from the high risk MI database initiative (pooled data from CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT). European Heart Journal. 604-604.
  • Show author(s) (2010). NT-proBNP is a potent prognostic marker in patients with type 2 diabetes hospitalized for acute coronary syndrome - a DIGAMI 2 sub study. European Heart Journal. 514-515.
  • Show author(s) (2010). Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction and prevents ischemic heart failure. European Heart Journal. 314-314.
  • Show author(s) (2010). Intravenous ferric carboxymaltose improves quality of life in patients with chronic heart failure and iron deficiency regardless the presence of anaemia: an analysis from the FAIR-HF study. European Heart Journal. 233-233.
  • Show author(s) (2010). Early increase in Stromelysin-1 levels is related to infarct size and predicts long-term LV remodelling following STEMI. European Heart Journal. 192-193.
  • Show author(s) (2010). Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Circulation. 2217-2217.
  • Show author(s) (2009). Circulating Markers of Collagen Turnover Following ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention Predict Infarct Size and Left Ventricular Volumes, Estimated by Serial Cardiac Magnetic Resonance Imaging for up to 1 Year. Circulation. S818-S818.
  • Show author(s) (2007). The relationship between N-terminal B-type natriuretic peptide and circulating markers of extracellular cardiac remodelling in patients following complicated myocardial infarction. European Journal of Heart Failure. 10-11.
  • Show author(s) (2004). What's new in the management of heart failure? Atherosclerosis Supplements.
  • Show author(s) (2004). Total mortality and sudden cardiac death are predicted by both left and right bundle branch block at baseline and during follow-up after complicated myocardial infarction. Circulation. A1032-A1032.
  • Show author(s) (2004). The relationship between the extent of myocardial scarring and left ventricular ejection fraction assessed by cardiac magnetic resonance in 57 patients with previous myocardial infarction. European Heart Journal. 599-599.
  • Show author(s) (2004). The longitudinal profile of markers of cardiac extracellular matrix turnover in patients following acute myocardial infarction. European Heart Journal.
  • Show author(s) (2004). Relative impact of renal function on circulating levels of brain-type natriuretic peptide an N-terminal-pro-brain-type natriuretic peptide in patients with postinfarction heart failure. European Heart Journal. 292-292.
  • Show author(s) (2004). Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction. The OPTIMAL experience. European Heart Journal. 299-299.
  • Show author(s) (2004). Moderate alcohol use is associated with reduced cardiovascular risk in patients following complicated acute myocardial infarction. JACC. 1153-1173.
  • Show author(s) (2004). Hemoglobin levels predict survival and hospitalization after a complicated acute myocardial infarction: Results from the OPTIMAAL study. Circulation. 574-575.
  • Show author(s) (2004). Haemoglobin levels predict survival and hospitalisation after a complicated acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. 305-305.
  • Show author(s) (2004). Effect of hypo- and hyperkalemia on mode of death in patients with heart failure following myocardial infarction. European Heart Journal.
  • Show author(s) (2003). Serial high-sensitivity CRP measurements and long-term prognosis in postinfarction heart failure. The OPTIMAAL neurohormonal substudy. Circulation.
  • Show author(s) (2003). Serial high-sensitivity CRP measurements and long-term prognosis in post-infarction heart failure. The OPTIMAAL neurohormonal study. Circulation. 692-692.
Academic literature review
  • Show author(s) (2020). 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 407-477.
  • Show author(s) (2019). Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. The Lancet. 1045-1055.
  • Show author(s) (2016). Telerehabilitation in heart failure patients: The evidence and the pitfalls. International Journal of Cardiology. 408-413.
  • Show author(s) (2015). The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology. 256-264.
  • Show author(s) (2013). Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure. 1082-1094.
  • Show author(s) (2012). The High-Risk Myocardial Infarction Database Initiative. Progress in cardiovascular diseases. 362-366.
  • Show author(s) (2010). Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure. 423-433.
  • Show author(s) (2008). Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure. 1229-1235.
  • Show author(s) (2008). Overview of emerging pharmacologic agents for acute heart failure syndromes. European Journal of Heart Failure. 201-213.
  • Show author(s) (2008). Guidelines 2008 European Society of Cardiology on the diagnosis and treatment of acute and chronic heart failure. Kardiologia polska. S389-S454.
  • Show author(s) (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal. 2388-442.
  • Show author(s) (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure. 933-989.
  • Show author(s) (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal. 2388-2442.
  • Show author(s) (2007). Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 684-694.
  • Show author(s) (2005). Diagnosis and assessment of the heart failure patient: the cornerstone of effective management. European Journal of Heart Failure. 303-308.

More information in national current research information system (CRIStin)